Product Description
ImmunityBio’s novel PD-L1 t-haNKs are derived from a human, allogeneic NK cell line (NK-92) that has been engineered to express IL-2, CD16, and a chimeric antigen receptor (CAR) that recognizes PD-L1.(https://immunitybio.com/immunitybio-announces-nih-led-research-affirming-that-pd-l1-t-hank-therapy-overcomes-t-cell-escape-in-multiple-types-of-resistant-tumors/)
Mechanisms of Action: IL2,CD16
Novel Mechanism: Yes
Modality: CAR-T
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Carcinoma, Merkel Cell|Cervical Cancer|Colorectal Cancer|Gastrointestinal Cancer|Glioblastoma|Head and Neck Cancer|Hepatocellular Carcinoma|Melanoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Uterine Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| QUILT-3.078 | P2 |
Recruiting |
Glioblastoma |
2029-12-31 |
|
| QUILT-3.055 | P2 |
Recruiting |
Cervical Cancer|Colorectal Cancer|Gastrointestinal Cancer|Renal Cell Carcinoma|Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Uterine Cancer|Head and Neck Cancer|Melanoma|Transitional Cell Carcinoma|Squamous Cell Carcinoma|Carcinoma, Merkel Cell |
2029-08-31 |
|
| QUILT-505 | P2 |
Recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer |
2025-07-31 |
|
| QUILT-3.064 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2024-10-31 |